Search This Blog

Monday, April 27, 2026

Compass tovecimig improves progression-free but not overall survival in Phase 2/3 biliary tract cancer

 

Compass Therapeutics' tovecimig improves progression-free but not overall survival in Phase 2/3 biliary tract cancer trial

  • Company plans FDA meeting ahead of a BLA submission based on COMPANION-002 biliary tract cancer data.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)